Laurus Synthesis and Epygenix Therapeutics have signed a collaboration agreement for the development and manufacture of EPX-100, an epilepsy candidate.
Epilepsy
Under the terms of the agreement, Laurus Synthesis will provide chemistry development services and manufacturing in support of an upcoming clinical trial for EPX-100 in adolescents suffering from Dravet syndrome.
“Epygenix is proud to be supported by Laurus in developing a new therapy for this devastating disease,” said Dr Hahn-Jun Lee, MSc, PhD, founder and CEO of Epygenix. “Our collaboration efforts with Laurus will be able to help many children who are suffering from this intractable genetic epilepsy.”
Dr Charles Montgomery, PhD, LSI's vice president chemistry, added, “This collaboration validates LSI's ability to assist companies with challenging chemistry development. Our goal is to outperform expectations so that our clients can reach their business milestones quickly and effectively.”